全文获取类型
收费全文 | 9689篇 |
免费 | 612篇 |
国内免费 | 45篇 |
专业分类
耳鼻咽喉 | 57篇 |
儿科学 | 242篇 |
妇产科学 | 143篇 |
基础医学 | 1387篇 |
口腔科学 | 30篇 |
临床医学 | 923篇 |
内科学 | 2453篇 |
皮肤病学 | 130篇 |
神经病学 | 821篇 |
特种医学 | 363篇 |
外科学 | 1756篇 |
综合类 | 27篇 |
一般理论 | 2篇 |
预防医学 | 415篇 |
眼科学 | 76篇 |
药学 | 623篇 |
中国医学 | 22篇 |
肿瘤学 | 876篇 |
出版年
2023年 | 53篇 |
2022年 | 94篇 |
2021年 | 236篇 |
2020年 | 130篇 |
2019年 | 254篇 |
2018年 | 258篇 |
2017年 | 205篇 |
2016年 | 211篇 |
2015年 | 275篇 |
2014年 | 345篇 |
2013年 | 436篇 |
2012年 | 736篇 |
2011年 | 753篇 |
2010年 | 430篇 |
2009年 | 412篇 |
2008年 | 608篇 |
2007年 | 649篇 |
2006年 | 623篇 |
2005年 | 685篇 |
2004年 | 593篇 |
2003年 | 566篇 |
2002年 | 582篇 |
2001年 | 92篇 |
2000年 | 83篇 |
1999年 | 110篇 |
1998年 | 133篇 |
1997年 | 78篇 |
1996年 | 73篇 |
1995年 | 52篇 |
1994年 | 62篇 |
1993年 | 55篇 |
1992年 | 46篇 |
1991年 | 45篇 |
1990年 | 45篇 |
1989年 | 32篇 |
1988年 | 39篇 |
1987年 | 30篇 |
1986年 | 22篇 |
1985年 | 23篇 |
1984年 | 21篇 |
1983年 | 20篇 |
1982年 | 16篇 |
1981年 | 18篇 |
1980年 | 13篇 |
1979年 | 22篇 |
1977年 | 7篇 |
1976年 | 14篇 |
1975年 | 7篇 |
1973年 | 8篇 |
1972年 | 7篇 |
排序方式: 共有10000条查询结果,搜索用时 12 毫秒
101.
Thierry Conroy Bernard Paillot Eric Fran?ois Roland Bugat Jacques-Henri Jacob Ulrich Stein Salvador Nasca Jean-Philippe Metges Olivier Rixe Pierre Michel Emmanuelle Magherini Aliette Hua Gael Deplanque 《Journal of clinical oncology》2005,23(6):1228-1236
PURPOSE: To evaluate response rate and toxicity of irinotecan and oxaliplatin plus fluorouracil (FU) and leucovorin (Folfirinox) in advanced pancreatic adenocarcinoma (APA). PATIENTS AND METHODS: Chemotherapy-naive patients with histologically proven APA and bidimensionally measurable disease were treated with Folfirinox therapy every 2 weeks, which comprised oxaliplatin 85 mg/m(2) and irinotecan 180 mg/m(2) plus leucovorin 400 mg/m(2) followed by bolus FU 400 mg/m(2) on day 1, then FU 2,400 mg/m(2) as a 46-hour continuous infusion. Quality of life (QOL) was assessed using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30). RESULTS: Forty-seven patients were entered, and 46 received treatment. Thirty-five patients (76%) had metastatic disease. A total of 356 cycles were delivered, with a median of eight cycles per patient (range, one to 24 cycles). All patients were assessable for safety. No toxic death occurred. Grade 3 to 4 neutropenia occurred in 52% of patients, including two patients with febrile neutropenia. Other relevant toxicities included grade 3 to 4 nausea (20%), vomiting (17%), and diarrhea (17%) and grade 3 neuropathy (15%; Levi's scale). The confirmed response rate was 26% (95% CI, 13% to 39%), including 4% complete responses. Median time to progression was 8.2 months (95% CI, 5.3 to 11.6 months), and median overall survival was 10.2 months (95% CI, 8.1 to 14.4 months). Between baseline and end of treatment, patients had improvement in all functional scales of the EORTC QLQ-C30, except cognitive functioning. Responders had major improvement in global QOL. CONCLUSION: With a good safety profile, a promising response rate, and an improvement in QOL, Folfirinox will be further assessed in a phase III trial. 相似文献
102.
Thierry M Muanza Ana P Cotrim Mathew McAuliffe Anastasia L Sowers Bruce J Baum John A Cook Felix Feldchtein Paul Amazeen C Norman Coleman James B Mitchell 《Clinical cancer research》2005,11(14):5121-5127
PURPOSE: Optical coherence tomography (OCT) imaging was evaluated to determine if radiation-induced mucosal damage could be noninvasively monitored in real time and correlated with histopathologic findings. EXPERIMENTAL DESIGN: Female C3H mice, ages 7 to 9 weeks, four per group, were immobilized in a custom-made Lucite jig and received 0, 15, 22.5, and 25 Gy in a single fraction to their oral cavity. OCT images were acquired of proximal, middle, and distal aspects of the dorsum of the tongue on days 0, 1, 3, 5, and 7 post-irradiation. Animals were sacrificed on day 7 and samples taken for histologic evaluation. OCT images were visually examined and also quantified by image analysis and compared with histologic findings. RESULTS: Tongues removed 7 days post-irradiation showed no visible damage; however, upon staining with toluidine blue, ulcers at the base of the tongue became visible (100% for 25 Gy, 75% after 22.5 Gy, and 0% after 15 Gy). Visual inspection of OCT images qualitatively compared with histologic findings and quantitative image analysis of the OCT images (effective light penetration depth) revealed significant changes 7 days post-irradiation compared with unirradiated controls for the base of the tongue. CONCLUSIONS: OCT allows for direct noninvasive real-time acquisition of digitally archivable images of oral mucosa and can detect radiation-induced changes in the mucosa before visual manifestation. OCT may be a useful technique to quantify subclinical radiation-induced mucosal injury in experimental chemoradiation clinical trials. 相似文献
103.
Xavier Leleu Ga?lle Le Friec Thierry Facon Laurence Amiot Renée Fauchet Bernadette Hennache Valérie Coiteux Ibrahim Yakoub-Agha Sylvain Dubucquoi Hervé Avet-Loiseau Claire Mathiot Régis Bataille Jean-Yves Mary 《Clinical cancer research》2005,11(20):7297-7303
Serum beta2-microglobulin, the light chain of the HLA class I molecular complex, remains one of the best survival prognostic factors in multiple myeloma, but other HLA class I molecules might be of interest in monoclonal gammopathies. In this study, we evaluate total soluble HLA class I (HLA-Is) and soluble HLA-G (HLA-Gs) in 103 patients with newly diagnosed multiple myeloma, 30 patients with monoclonal gammopathy of undetermined significance (MGUS), and 30 healthy subjects, studying their prognostic value in multiple myeloma. In multiple myeloma patients, HLA-Is and HLA-Gs median values were 0.8 microg/mL and 28 ng/mL, respectively. Median HLA-Is concentration was higher in stage II and III multiple myeloma patients than in stage I multiple myeloma, MGUS, and control patients. Median HLA-Gs was significantly lower in healthy controls than in MGUS and multiple myeloma patients. A high level of HLA-Is (> or =2.1 microg/mL) was predictive of short survival (P = 0.017). For each given level of beta2-microglobulin, the relative risk of death was higher for patients with HLA-Is > or = 2.1 microg/mL than in patients with a lower level (P = 0.047). HLA-Gs, a marker of monoclonal gammopathy, was of no prognostic value, but the addition of HLA-Is to beta2-microglobulin produced an efficient prognostic score (P < 0.0001). HLA-Is is a new marker of multiple myeloma tumor load and provides additional survival prognostic information to beta2-microglobulin. 相似文献
104.
Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. 总被引:7,自引:0,他引:7
Sandrine Ostermann Chantal Csajka Thierry Buclin Serge Leyvraz Ferdy Lejeune Laurent A Decosterd Roger Stupp 《Clinical cancer research》2004,10(11):3728-3736
PURPOSE: Scarce information is available on the brain penetration of temozolomide (TMZ), although this novel methylating agent is mainly used for the treatment of malignant brain tumors. The purpose was to assess TMZ pharmacokinetics in plasma and cerebrospinal fluid (CSF) along with its inter-individual variability, to characterize covariates and to explore relationships between systemic or cerebral drug exposure and clinical outcomes. EXPERIMENTAL DESIGN: TMZ levels were measured by high-performance liquid chromatography in plasma and CSF samples from 35 patients with newly diagnosed or recurrent malignant gliomas. The population pharmacokinetic analysis was performed with nonlinear mixed-effect modeling software. Drug exposure, defined by the area under the concentration-time curve (AUC) in plasma and CSF, was estimated for each patient and correlated with toxicity, survival, and progression-free survival. RESULTS: A three-compartment model with first-order absorption and transfer rates between plasma and CSF described the data appropriately. Oral clearance was 10 liter/h; volume of distribution (V(D)), 30.3 liters; absorption constant rate, 5.8 h(-1); elimination half-time, 2.1 h; transfer rate from plasma to CSF (K(plasma-->CSF)), 7.2 x 10(-4)h(-1) and the backwards rate, 0.76 h(-1). Body surface area significantly influenced both clearance and V(D), and clearance was sex dependent. The AUC(CSF) corresponded to 20% of the AUC(plasma). A trend toward an increased K(plasma-->CSF) of 15% was observed in case of concomitant radiochemotherapy. No significant correlations between AUC in plasma or CSF and toxicity, survival, or progression-free survival were apparent after deduction of dose-effect. CONCLUSIONS: This is the first human pharmacokinetic study on TMZ to quantify CSF penetration. The AUC(CSF)/AUC(plasma) ratio was 20%. Systemic or cerebral exposures are not better predictors than the cumulative dose alone for both efficacy and safety. 相似文献
105.
Arnaud Scherpereel Julien Mazieres Laurent Greillier Sylvie Lantuejoul Pascal Dô Olivier Bylicki Isabelle Monnet Romain Corre Clarisse Audigier-Valette Myriam Locatelli-Sanchez Olivier Molinier Florian Guisier Thierry Urban Catherine Ligeza-Poisson David Planchard Elodie Amour Franck Morin Denis Moro-Sibilot Delphine CARMIER 《The lancet oncology》2019,20(2):239-253
106.
Copy number variations in DCC/18q and ERBB2/17q are associated with disease‐free survival in microsatellite stable colon cancer 下载免费PDF全文
David Sefrioui Thomas Vermeulin France Blanchard Caroline Chapusot Ludivine Beaussire Laura Armengol‐Debeir Richard Sesboué Alice Gangloff Mohamed Hebbar Marie‐Christine Copin Estelle Houivet Lilian Schwarz Florian Clatot Jean‐Jacques Tuech Jacques Bénichou Laurent Martin Anne‐Marie Bouvier Jean‐Christophe Sabourin Nasrin Sarafan‐Vasseur Thierry Frébourg Côme Lepage Pierre Michel Frédéric Di Fiore 《International journal of cancer. Journal international du cancer》2017,140(7):1653-1661
We conducted a prospective study to assess the prognostic impact of selected copy number variations (CNVs) in Stage II–III microsatellite stable (MSS) colon cancer. A total of 401 patients were included from 01/2004 to 01/2009. The CNVs in 8 selected target genes, DCC/18q, EGFR/7p, TP53/17p, BLK/8p, MYC/8q, APC/5q, ERBB2/17q and STK6/20q, were detected using a quantitative multiplex polymerase chain reaction of short fluorescent fragment (QMPSF) method. The primary end‐point was the impact of the CNVs on the 4‐year disease‐free survival (DFS). The recurrence rate at 4 years was 20.9%, corresponding to 14% Stage II patients versus 31% Stage III patients (p < 0.0001). The 4‐year DFS was significantly decreased in patients with a loss at DCC/18q (p = 0.012) and a gain at ERBB2/17q (p = 0.041). The multivariate analysis demonstrated that Stage III, a loss at DCC/18q and a gain at ERBB2/17q were independent factors associated with DFS. A combination of DCC/18q and ERBB2/17q was also associated with relapse, with the hazard ratio increasing from 1 to 2.4 (95% confidence interval (CI), 1.5–4.1) and 3.1 (95% CI, 1.2–8.4) in the presence of 0, 1 or 2 alterations, respectively (p = 0.0013). CNVs in DCC/18q and ERBB2/17q are significantly associated with DFS in Stage II–III MSS colon cancer. 相似文献
107.
Les points chauds de l’actualité en 2017. Une sélection du comité de rédaction du Bulletin du Cancer
108.
Benoît Renaud Caroline-Julia Kruse Anne-Christine Franois Lisa Grund Carolin Bunert Lucie Brisson Franois Boemer Gilbert Gault Barbara Ghislain Thierry Petitjean Pascal Gustin Dominique-Marie Votion 《Toxins》2022,14(8)
Acer pseudoplatanus is a worldwide-distributed tree which contains toxins, among them hypoglycin A (HGA). This toxin is known to be responsible for poisoning in various species, including humans, equids, Père David’s deer and two-humped camels. We hypothesized that any herbivore pasturing with A. pseudoplatanus in their vicinity may be at risk for HGA poisoning. To test this hypothesis, we surveyed the HGA exposure from A. pseudoplatanus in species not yet described as being at risk. Animals in zoological parks were the major focus, as they are at high probability to be exposed to A. pseudoplatanus in enclosures. We also searched for a toxic metabolite of HGA (i.e., methylenecyclopropylacetyl-carnitine; MCPA-carnitine) in blood and an alteration of the acylcarnitines profile in HGA-positive animals to document the potential risk of declaring clinical signs. We describe for the first instance cases of HGA poisoning in Bovidae. Two gnus (Connochaetes taurinus taurinus) exposed to A. pseudoplatanus in their enclosure presented severe clinical signs, serum HGA and MCPA-carnitine and a marked modification of the acylcarnitines profile. In this study, even though all herbivores were exposed to A. pseudoplatanus, proximal fermenters species seemed less susceptible to HGA poisoning. Therefore, a ruminal transformation of HGA is hypothesized. Additionally, we suggest a gradual alteration of the fatty acid metabolism in case of HGA poisoning and thus the existence of subclinical cases. 相似文献
109.
Wendimi Fatimata Belem Ching-Hsuan Liu Yee-Tung Hu Thierry Burnouf Liang-Tzung Lin 《Viruses》2022,14(11)
Therapeutic blood products including convalescent plasma/serum and immunoglobulins concentrated from convalescent plasma, such as intravenous immunoglobulins or hyperimmune globulins, and monoclonal antibodies are passive immunotherapy options for novel coronavirus disease 2019 (COVID-19). They have been shown to improve the clinical status and biological and radiological parameters in some groups of COVID-19 patients. However, blood products are still potential sources of virus transmission in recipients. The use of pathogen reduction technology (PRT) should increase the safety of the products. The purpose of this study was to determine the impact of solvent/detergents (S/D) procedures on SARS-CoV-2 infectivity elimination in the plasma of donors but also on COVID-19 convalescent serum (CCS) capacity to neutralize SARS-CoV-2 infectivity. In this investigation, S/D treatment for all experiments was performed at a shortened process time (30 min). We first evaluated the impact of S/D treatments (1% TnBP/1% TritonX-45 and 1% TnBP/1% TritonX-100) on the inactivation of SARS-CoV-2 pseudoparticles (SARS-CoV-2pp)-spiked human plasma followed by S/D agent removal using a Sep-Pak Plus C18 cartridge. Both treatments were able to completely inactivate SARS-CoV-2pp infectivity to an undetectable level. Moreover, the neutralizing activity of CCS against SARS-CoV-2pp was preserved after S/D treatments. Our data suggested that viral inactivation methods using such S/D treatments could be useful in the implementation of viral inactivation/elimination processes of therapeutic blood products against SARS-CoV-2. 相似文献
110.
Hassane Zouhal Benjamin Barthlmy Alexandre Dellal Sghaeir Zouita Abderraouf Ben Abderrahman Omar Ben Ounis Claire Tourny Ali Belamjahad Said Ahmaidi Thierry Paillard Nicolas Dyon Benoit Bideau Ayoub Saeidi Jason Moran Anis Chaouachi George P. Nassis Christopher Carling Urs Granacher Guillaume Rav 《Journal of Sports Science and Medicine》2022,21(3):482